The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 30 drug formulations, covering medicines used for diabetes, high blood pressure, heart disease, infections, and women's health. This move is expected to significantly reduce treatment costs for patients who depend on long-term medication.
Drugs Covered Under the Notification
The latest notification includes several drugs commonly prescribed for chronic illnesses that affect millions of Indians, many of which require long-term or lifelong treatment. The formulations include anti-diabetic combinations containing empagliflozin, sitagliptin, metformin, teneligliptin, and dapagliflozin; heart medicines containing atorvastatin, telmisartan, cilnidipine, and metoprolol; antibiotics for infections; pain-relief drugs; vitamin supplements; and medicines used for women's health conditions.
Maximum Retail Prices Set
The notification fixes the maximum retail price at which these formulations can be sold, excluding GST. Manufacturers will not be allowed to market them above the notified rates. Key formulations include empagliflozin-sitagliptin-metformin tablets priced at Rs 14.88 per tablet, sitagliptin-glimepiride-metformin tablets at Rs 11.91 per tablet, teneligliptin-dapagliflozin tablets at Rs 10.17 per tablet, and atorvastatin-fenofibrate tablets at Rs 18.46 per tablet. Tacrolimus capsules used by organ transplant patients have been priced at Rs 127 per capsule.
The list also includes vitamin D3 oral solutions, calcium and vitamin supplements, cefpodoxime-clavulanate antibiotic suspensions for children, and norethisterone acetate tablets for women's health.
Industry and Expert Reactions
Industry representatives said the notified prices for several commonly used medicines are lower than prevailing market rates. However, market prices may vary across brands and strengths. Rajiv Singhal, general secretary of the All India Organisation of Chemists and Druggists, welcomed the move and said consumers are likely to gain from revised prices in 60-90 days, once existing stocks in the supply chain are cleared and the revised MRP stock reaches the market.
Health experts note that medicines account for a significant share of household healthcare spending in India, particularly for patients living with chronic conditions such as diabetes, hypertension, and heart disease. Affordable access to treatment is considered critical for reducing the financial burden on families and improving adherence to long-term therapy.
